As of November 15, 2026, Intellia Therapeutics, Inc. is a publicly traded company (Nasdaq: NTLA); its largest reported holder is ARK Invest, with 12.27% on Schedule 13G/A of February 3, 2026, then State Street (5.6%). The largest insider holding is John M. Leonard, the chief executive and president, with 1,196,479 shares (0.85% of shares outstanding), per Form 4 of November 3, 2026 (Schedule 13G/A, February 3, 2026).
Is this your company?
About to sign with, pay or invest in Intellia Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Intellia Therapeutics, Inc. a real, registered company?
- Intellia Therapeutics, Inc. files with the SEC under CIK 1652130 (its SEC filings).
- Its shares are listed under the ticker NTLA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under INTELLIA THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-15).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2025-01-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names State Street (filed 2026-11-10).
Who are Intellia Therapeutics, Inc.'s owners and officers?
Intellia Therapeutics, Inc.: incorporated in Delaware; business address in Cambridge, Massachusetts; industry In Vitro & In Vivo Diagnostic Substances (Schedule 13G, 2026-11-10).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-10 | State Street Corporation | 5.6% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 6.8% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.03% |
| Schedule 13G, 2026-04-29 | Vanguard Portfolio Management | 5.3% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-12 | The Goldman Sachs Group, Inc. | 2.7% |
| Schedule 13G/A, 2026-02-11 | Contrarius Investment Management LTD | 0.6% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 5.5% |
| Schedule 13G/A, 2026-02-03 | Ark Investment Management LLC | 12.27% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 11.23% |
| Schedule 13G, 2025-11-12 | The Goldman Sachs Group, Inc. | 5.1% |
| Schedule 13G, 2025-11-12 | Contrarius Investment Management LTD | 5.5% |
Questions about who owns Intellia Therapeutics, Inc.
Who owns Intellia Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Intellia Therapeutics, Inc.: Ark Investment Management LLC (12.27%, Schedule 13G/A, filed 2026-02-03), State Street Corporation (5.6%, Schedule 13G, filed 2026-11-10), Vanguard Portfolio Management (5.3%, Schedule 13G, filed 2026-04-29) and Vanguard Capital Management (5.03%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Intellia Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Intellia Therapeutics, Inc. on this page are Ark Investment Management LLC (12.27%), State Street Corporation (5.6%) and Vanguard Portfolio Management (5.3%).
When did Ark Investment Management LLC buy into Intellia Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ark Investment Management LLC on this page is the Schedule 13G/A, filed 2026-02-03, reporting 12.27%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Intellia Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Intellia Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Intellia Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Intellia Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 1,196,479 shares (0.85% of shares outstanding), 1,138,064 held directly and 58,415 indirectly (Form 4, 2026-11-03).
- , a director: 216,653 shares (0.15% of shares outstanding) (Form 4, 2026-06-10).
- , the executive vice president and chief medical officer: 199,822 shares (0.14% of shares outstanding) (Form 4, 2026-10-28).
- , the general counsel and executive vice president: 156,794 shares (0.11% of shares outstanding) (Form 4, 2026-03-03).
- , the chief financial officer and executive vice president: 148,175 shares (0.11% of shares outstanding) (Form 4, 2026-07-24).
Shares outstanding: 140,358,512 as of 2026-10-30, from the company's latest SEC cover page.
How much has Intellia Therapeutics, Inc. raised?
No fundraising or offering filing from Intellia Therapeutics, Inc. is on file with us.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2025-01-10).
Keep reading
More on Intellia Therapeutics, Inc. and the records around it.
Companies that share a holder
- Contrarius Investment Management Ltd also filed stake reports on 1 other company: QVC Group, Inc. (Nov 2026)
- ARK Investment Management LLC also filed stake reports on 23 other companies: Beam Therapeutics Inc. (Nov 2026), CERUS CORP (Nov 2026), CRISPR Therapeutics AG (Nov 2026)
- THE GOLDMAN SACHS GROUP, INC. also filed stake reports on 183 other companies: Attovia Therapeutics, Inc. (Nov 2026), OSPREY ACQUISITION CORP. III (Nov 2026), ALLIED GOLD CORPORATION (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/intellia-therapeutics